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Introduction: Corpus luteum (CL) produces progesterone (P4) and 17-OH progesterone
(17-OHP4) during the luteal phase. Contrary to P4, 17-OHP4 is not supplied as part of the
luteal phase support following IVF-treatment. Therefore, measuring endogenous serum
17-OH P4 levels may more accurately reflect the CL function compared to monitoring
serum P4 concentrations.
Objective: To explore the correlation betweenmid-luteal serum 17-OH P4 levels and live
birth rates and to explore the possible daytime variations in mid-luteal serum 17-OH P4.
Design: Prospective cohort study.
Patients: 614 women undergoing IVF-treatment and fresh embryo transfer.
Intervention: All patients had serum 17-OH P4 measured 7 days after oocyte pick-up
(OPU+7). Furthermore, on OPU+7, seven patients underwent repeated blood sampling
during daytime to clarify the endogenous daytime secretory pattern of 17-OH P4.
Outcome measure: Live birth rate.
Secondary outcome measure: Daytime variation in serum 17-OH P4 levels.
Results: The highest chance of a live birth was seen with mid-luteal 17-OH P4 between
6.0 and 14.0 nmol/l. The chance of a live birth was reduced below (RD −10%, p =
0.07), but also above the optimal range for 17-OH P4 (RD −12%, p = 0.04). Patients
with diminished CL-function (17-OH P4 <6 nmol/l) displayed clinically stable 17-OH P4
values, whereas patients with 17-OH P4 levels >6 nmol/l showed random 17-OH P4
fluctuations during daytime.
Conclusion: The association between 17-OH P4 and reproductive outcomes is non-
linear, and the negative effect of excessive CL-secretion seems to be just as strong as
the negative effect of a reduced CL-function during the peri-implantation period.
Keywords: 17-OH progesterone, progesterone, IVF, live birth, daytime variation
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INTRODUCTION
Following ovulation, the human corpus luteum (CL) produces
progesterone (P4) and 17-OH progesterone (17-OH P4) upon
stimulation with luteinizing hormone (LH) or human chorionic
gonadotropin (hCG). Progesterone governs the secretory
transformation of the endometrium prior to implantation and
an adequate luteal P4 level is crucial for the establishment and
maintenance of early pregnancy (1).
During IVF and fresh embryo transfer, the luteal function is
disrupted and the success of the treatment is critically dependent
on exogenous luteal phase support (2–5). For decades, this
exogenous P4 support has been administered as a standard dose
in IVF patients in the firm belief that “one dose fits all.” A
widely held view has been that the absolute luteal P4 level does
not affect the chance of pregnancy, as long as a minimum P4
concentration was reached by means of the administration of
exogenous luteal phase support (6, 7). However, recent studies
have suggested that both very low and very high luteal P4
levels affect the reproductive outcome negatively (8–12). Thus,
in a study by Yovich et al., 529 artificial frozen-thawed cycles
with single blastocyst transfer were evaluated (8). The authors
reported that the optimal pregnancy and live birth rate was
achieved when mid-luteal serum P4 was in the range of 70–99
nmol/l. Below, but also above this range, the clinical pregnancy
rate was significantly reduced from 64 to 44%. Following this,
several other papers also reported a lower, as well as, higher luteal
P4 threshold in artificial frozen-thawed embryo transfer cycles
(10–12). In IVF cycles with fresh embryo transfer, the mid-luteal
P4 requirement is significantly increased compared to both the
natural and the frozen embryo transfer cycle as demonstrated by
a work byHumaidan et al. (2). Very recently, our group described
the optimal P4 levels during the early andmid-luteal phase of IVF
cycles with fresh embryo transfer (9). In a cohort of 602 patients,
we observed that reproductive outcomes seemed consistently
decreased below, but most distinctly above a defined optimal
P4 range.
Taken together, it seems that both too high and too low
luteal P4 concentrations result in reduced pregnancy rates in
both fresh and frozen embryo transfer cycles. The findings of a
higher and lower P4 threshold seem plausible from a biological
point of view: A very high P4 level during the early luteal phase
may advance the endometrium leading to asynchrony between
embryo development and endometrial receptivity, whereas a very
low P4 level fails to support a sufficient secretory transformation
in time for implantation. Both scenarios hamper the chance of a
live birth.
The CL produces not only P4, but also 17-OH P4 during its
lifespan (13). When measuring serum P4 following fresh embryo
transfer with the use of exogenous P4 luteal support, the serum
P4 value is a combination of the exogenously supplied P4 and the
endogenous luteal P4 production. As 17-OH P4 is not supplied
as part of the luteal phase support, the serum 17-OH P4 level
may reflect more accurately the true CL function compared to
the measurement of total P4.
The aim of this study was to explore the possible correlation
between mid-luteal serum 17-OH P4 levels and the reproductive
outcome in terms of live birth rates following IVF treatment and
fresh embryo transfer. Furthermore, if serum 17-OH P4 should
serve as an index for CL function, it is evident that the accuracy
of a single measurement is important. Therefore, a second aim of
the present study was to explore the daytime variations in serum
17-OH P4 which might affect the clinical interpretation of the
measurement.
MATERIALS AND METHODS
Study Design
Prospective cohort study.
Patient Population
The present cohort of patients has previously been described
in papers by our group (9, 14). Briefly, this study included
614 patients undergoing IVF treatment at four public Danish
fertility centers—The Fertility Clinic Skive Region Hospital, The
Fertility Clinic Horsens Region Hospital, The Fertility Clinic
Herlev Hospital and The Fertility Clinic Odense University
Hospital—between May 2014 and June 2017. The patient cohort
was unselected, representing normal everyday patients treated
in the clinics. All participating patients were under the age of
41 and with a body mass index (BMI) <35 kg/m2 as required
by Danish national guidelines for public fertility treatment1
Treatment choices regarding type of protocol (GnRH agonist or
GnRH antagonist) and trigger type (hCG or GnRH agonist) were
made on an individual basis by the attending clinician.
Written and oral information was given to 1,482 patients of
whom 609 (41%) declined to participate mainly due to the extra
visit needed at the clinic for mid-luteal blood sampling 7 days
after oocyte retrieval (OPU+7). The final study cohort included
614 patients with embryo transfer and relevant study samples
taken (Figure 1).
Clinical information regarding primary diagnosis, age, BMI,
smoking habits, antral follicle count and basal FSH and LH levels
were obtained prior to treatment by the clinical staff. Serum TSH
and prolactin levels were within normal range in all patients
prior to treatment start. All patients participated once, only. No
patients were lost to follow-up.
Ovarian Stimulation
Patients treated in the long GnRH-agonist protocol were
down-regulated using daily SC injections of a GnRH antagonist
(Suprefact R©, Sanofi, Denmark or Gonapeptyl R©, Ferring
Pharmaceuticals, Denmark) starting in the mid-luteal phase of
the preceding cycle and continuing until the day before ovulation
induction. Ovarian stimulation was initiated after 12–14 days of
down-regulation in case of an endometrial thickness <4mm.
Final follicle maturation was induced with hCG 5,000–10,000
IU (Pregnyl R©, MSD, Denmark or Ovitrelle, Merck Biopharma,
Denmark) when two or more leading follicles reached a diameter
of ≥17mm.
1Danish Fertility Society. Guideline 2016: Overweight, Obesity and Fertility
Treatment.
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FIGURE 1 | Flowchart of study participation.
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If the GnRH antagonist protocol was used, ovarian
stimulation commenced on day 2 or 3 of the cycle
after a vaginal ultrasound examination. Daily GnRH
antagonist co-treatment was started from cycle day 6
and continued up until the day of ovulation induction.
When at least two follicles reached a size of ≥17mm, final
oocyte maturation was induced with SC Buserelin 0.5mg
(Suprefact R©, Sanofi, Denmark) or hCG 5,000–10,000 IU
(Pregnyl R©, MSD, Denmark or Ovitrelle, Merck Biopharma,
Denmark).
Ovarian stimulation was performed with either hMG
(Menopur R©, Ferring Pharmaceuticals, Denmark), r-FSH (Gonal-
f R©, Merck Biopharma, Denmark), or rFSH/LH (Pergoveris,
Merck Biopharma, Denmark) alone or in combination with
corifollitropin-alfa (Elonva, MSD, Denmark). The initial
gonadotropin dosage was determined individually based on
previous response to ovarian stimulation, as well as, patient age,
body mass index, antral follicle count, and basal levels of follicle
stimulating hormone (FSH). Dose adjustments were performed
according to ovarian response monitored by transvaginal
ultrasound during treatment. Oocyte pick-up (OPU) was carried
out 36 h after trigger administration. In vitro fertilization (IVF)
or intracytoplasmic sperm injection (ICSI) was performed
according to normal clinical practice. A maximum of two
embryos were transferred on either days 2, 3, or 5 following
oocyte retrieval.
Trained embryologists on site evaluated the quality of all
available embryos. All original embryo scores from the four
clinics were subsequently evaluated by two independent leading
embryologists and allocated a final score from 1 to 3 (1 being
a top-quality embryo, 2 being an intermediate embryo, 3 being
a low-quality embryo). In case of incongruence, a second
evaluation was performed to reach final agreement.
Briefly, a top-quality embryo on day 2 and 3 was described
as having four and eight cells, respectively, equally sized
blastomeres, <10% fragmentation and no multinucleate cells in
accordance with the consensus scoring system for cleavage-stage
embryos described by the Alpha Scientist group (15). In case
of severe fragmentation (>25%), cell-size not stage-specific or
evidence of multinucleation the cleavage embryo was classified
as low-quality. The remaining cleavage embryos were classified
as intermediate.
A top-quality blastocyst had a day 5 score better than 3BB
according to the Gardner standard based on grade of expansion,
trophectoderm, and inner-cell mass quality (16). A low-quality
blastocyst had a day 5 score <3BB. The remaining blastocysts
(3BB, 4BB, 5BB) were described as intermediate.
Luteal Phase Support
All patients received the same vaginal luteal phase support in a
standard regimen using 300mg micronized P4 daily (Lutinus
R©,
Ferring Pharmaceuticals). Intramuscular P4 for luteal support
was not used in any of the participating patients. A small fraction
of patients (n= 41) had one bolus of GnRH agonist (Gonapeptyl
0.1mg) on OPU+7 based on an individual clinical assessment.
In patients receiving Gonapeptyl R©, 30/41 were treated in the
long GnRH agonist protocol and 11/41 in the GnRH antagonist
protocol. Patients receiving a bolus of GnRH as luteal phase
support were distributed equally across the different 17-OH P4
groups (p= 0.35).
In case of a GnRH-agonist trigger, a bolus of hCG on the day
of oocyte retrieval (1,500 IU) was given to all patients. Based
on the individual ovarian response to stimulation, some patients
received an additional bolus of HCG on OPU+5 according to a
protocol previously described by Humaidan et al. (17). Vaginal
P4 administration continued until the day of pregnancy testing
(hCG trigger) or until 7 completed weeks of gestation (GnRHa
trigger).
Blood Sampling
All 614 patients had blood samples performed 7 days after oocyte
pick-up (OPU+7) for hormone measurements and 14 days after
oocyte pick-up (OPU+14) for pregnancy testing.
On OPU+7, seven patients agreed to have a series of
blood samples performed during daytime to assess the possible
variation in serum 17-OH P4 levels over time. These seven
women were admitted to the fertility unit at Skive Region
Hospital early in the morning and stayed at the clinic for
the subsequent 12 h. The starting time for blood sampling
was between 6 and 8 a.m. for all patients. Participants were
allowed normal daily life activities during the study period. An
intravenous cannula was inserted into a vein in the antecubital
fossa and blood samples (4ml) were drawn every 60min for 12 h
(n = 7) and for two of these hours every 15min (n = 6 because
of difficult venous access in one patient).
After coagulation at room temperature, all blood samples
were centrifuged, and serum was isolated and divided into three
separate aliquots to allow for analyses at different laboratories.
Individual serum samples were stored at −80◦C until analysis.
Blood samples from the total cohort (n= 614) were analyzed for
17-OHP4 and P4, whereas the series of blood samples in the small
cohort (n= 7) were analyzed for 17-OH P4 and LH.
Hormone Assays
Serum 17-OH progesterone concentrations were measured using
liquid chromatography-tandemmass spectrometry (LC-MS/MS)
at the Department of Biochemistry, Aarhus University Hospital,
Denmark. The assay allowed quantification of 17-OH P4 in the
range 0.37–78.7 nmol/l without dilution of samples. The accuracy
was ± 0.32 nmol/l at 17-OH P4 concentrations of 1.3, ± 0.90
nmol/l at 17-OH P4 concentrations of 6.4 and ± 6.6 nmol/l at
17-OH P4 concentrations of 47.0 nmol/l.
Serum P4 and serum β-hCG concentrations were measured
at the Department of Biochemistry, Odense University
Hospital, Denmark using commercial automated electro
chemiluminescent immunoassays (Immulite R© 2000XPi,
Siemens Healthcare, Denmark and Architect R© i2000SR,
Abbott Diagnostics, USA) routinely used for analysis. Serum
LH concentrations were measured at the Department of
Biochemistry, Viborg Region Hospital, Denmark, using
commercial automated electro chemiluminescent immunoassays
(Cobas R© Modular analytics E170, Roche Diagnostics,
Switzerland). The detection limit for P4 was 0.6 nmol/l,
and the in-house inter- and intra-assay coefficients of variation
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were 4.4 and 1.6%, respectively. The detection limit for hCG
was 1.2 IU/l and the in-house inter- and intra-assay coefficients
of variation were 3.4 and 1.7%, respectively. The detection limit
for LH was 0.1 IU/l and the in-house inter- and intra-assay
coefficients of variation were 3.8 and 1.8%, respectively.
Exposure
Patients were divided into four 17-OH P4 groups based on raw
data of pregnancy outcomes: 17-OH P4 <6, 6–14, 14.1–30, and
>30 nmol/l (Supplementary Figure 1). The lower threshold of
6 nmol/l corresponds to the mid-luteal 17-OH P4 level of the
natural cycle (18).
In sensitivity analyses, estimates were also calculated based
on 25/50/75 percentiles, as well as, 10/50/90 percentiles
(Supplementary Figure 1).
Outcome Variables
Serum β-hCG concentration was determined on OPU+14 and
was considered positive if β-hCG >10 IU/l. In case of a β-hCG
level between 10 and 45 IU/l, a control β-hCG was performed
after 48 h. Clinical pregnancy was defined as the presence of a
live fetus within an intra-uterine gestational sac at ultrasound
examination in gestational weeks 7–8. Early pregnancy loss was
defined as (1) patients with an insufficient β-hCG value at the
day of pregnancy testing (10–45 IU/l) and decreasing β-hCG
values toward null in subsequent hCG-controls (2) patients with
a positive hCG but no intra- or extrauterine sac visualized on
transvaginal ultrasound in gestational weeks 7–8, and (3) patients
with a fetus without visible heartbeat at UL in gestational weeks
7–8. Clinical pregnancy loss was defined as the loss of a viable
intrauterine pregnancy up to and including gestational weeks
20+0. Live birth was defined as the delivery of a live infant
after gestational weeks 20+0. For description of gestational age,
clinical gestational dating was applied using the day of oocyte
retrieval as gestational weeks 2+0.
Confounding Factors
The confounding factors included in the regression model were
chosen a priori based on a Directed Acyclic Graph (DAG)
(Supplementary Figure 2). DAGs are visual representations of
causal paths between exposure and outcome (19, 20). Drawing
and analysis of a DAG can help to identify confounding factors
that obscure the real effect of the exposure on the outcome. Based
on a structured analysis of the DAG, it is possible to identify a
minimum, however sufficient set of covariates to adjust for in
the statistical analysis, which will cover all confounding elements.
The web application DAGitty was used to draw and analyze the
DAGs used in this paper.
Statistical Methods
Data are presented as mean and standard deviation for
continuous parametric variables, percentages for categorical
variables and median and range for continuous, non-parametric
variables. Differences in categorical variables between 17-
OH P4 groups were assessed with Fishers exact test or
Pearson’s chi-square test when appropriate. Differences in
continuous parametric data between the four 17-OH P4-
groups were assessed using one-way analysis of variance
(ANOVA) followed by a post-hoc pairwise comparison in
case of a statistical difference between groups. Normality
was checked by QQ-plots, and the assumption of variance
homogeneity was tested by Bartlett’s test. Kruskal-Wallis
test was used in case of non-parametric continuous
data.
A multiple logistic regression model was used to assess
the association between mid-luteal 17-OH P4 levels and the
hCG test result (positive/negative), clinical pregnancy (yes/no)
and early pregnancy loss (yes/no), and live birth (yes/no).
The model included the independent variables maternal age
(continuous, ln-transformed), maternal BMI (continuous, ln-
transformed), smoking (yes/no), final follicle count on the
day of trigger (continuous, ln-transformed), late follicular
phase P4 level [dichotomous (>4.77 or ≤4.77 nmol/l)] and
day of transfer [dichotomous (cleavage-stage or blastocyst)]
for estimates of positive hCG rate, clinical pregnancy rate,
and live birth rate. For estimates of early pregnancy loss
adjustment was made for maternal age (continuous, ln-
transformed), maternal BMI (continuous, ln-transformed),
smoking (dichotomous), final follicle count (continuous, ln-
transformed), day of transfer [dichotomous (cleavage-stage or
blastocyst)] and peak estradiol level on the day of trigger
(continuous, ln-transformed). The cut-off for late follicular
phase progesterone (>4.77 ng/ml equivalent to >1.5 ng/ml)
was chosen based on the results of earlier studies (21,
22).
In case of missing data of covariates, patients were omitted
from the final regression analysis (n = 72). A p < 0.05 was
considered statistically significant. All statistical analyses were
performed using STATA version 13.
Ethics
The study was conducted according to the declaration of
Helsinki for Medical Research and approved by the local
Ethics Committee of Central Denmark Region (M-2012-423-
12). All patients gave their written and oral consent prior
to study participation. ClinicalTrial.gov registration number
NCT02129998.
RESULTS
Demographic Data
The population consisted of 614 women undergoing IVF/ICSI
treatment followed by fresh embryo transfer on either days
2, 3, or 5. Demographic data are shown in Table 1. Overall,
patients had a mean age of 32.5 ± 4.6 years and a mean
BMI of 25.1± 4.2 kg/m2. Maternal age, basal LH, basal
FSH and smoking did not differ between 17-OH P4 groups.
Paternal age and BMI showed no significant differences between
17-OH P4 groups (data not shown). Maternal BMI was
significantly higher in the low 17-OH P4 group (17-OH P4
<6 nmol/l) compared pairwise to any of the other 17-OH
P4 groups (all pairwise p < 0.001). Antral follicle count and
the distribution of women with PCOS differed significantly
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TABLE 1 | Baseline characteristics of study patients in different 17-OH P4 groups.
17-OH P4 (nmol/l) N All <6 6–14 14.1–30 >30 p
Number of patients, n 614 183 134 132 165
Maternal age, years 614 32.5 ± 4.6 33.0 ± 4.9 32.2 ± 4.6 32.7 ± 4.5 32.0 ± 4.2 0.195
Maternal BMI, kg/m2 614 25.1 ± 4.2 26.3 ± 4.0 24.2 ± 4.1 24.7 ± 4.4 24.5 ± 4.1 <0.001
Maternal smoking,% 614 8 10 8 4 9 0.197
Basal FSH, IU 573* 6.2
(0.1–22.0)
6.1
(0.3–22.0)
6.7
(0.1–17.5)
6.4
(0.3–15.5)
6.0
(1.1–14.7)
0.544
Basal LH, IU 554** 5.4
(0.1–40.0)
5.2
(0.2–40.0)
5.2
(0.1–19.0)
5.4
(0.1–17.0)
5.6
(0.4–24.0)
0.792
Antral follicle count, n 614 13
(2–50)
12
(2–33)
14
(3–40)
12
(2–38)
13
(4–50)
0.004
Primary diagnosis,
Unexplained, %
Tubal, %
PCO/PCOS, %
Endometriosis, %
Male, %
Single/female partner, %
Other, %
614
25
9
11
6.5
38
10
1
21
7
11
7
39
14
1
22
8
13
7
45
5
0
30
11
5
7
37
9
1
29
11
14
5
30
10
1
0.200***
0.426
0.028
0.781
0.074
0.095
0.895
Baseline characteristics are presented as mean ± SD for continuous parametric data and as median (range) for continuous non-parametric data. Categorical data is presented as
percentages (%).*Data on basal FSH levels were missing in 41 patients (6.7%). Patients with missing data on basal FSH levels were equally distributed across 17-OH P4 groups (p =
0.49). ** Data on basal LH levels were missing in 60 patients (9.8%). Patients with missing data on basal LH levels were equally distributed across 17-OH P4 groups (p = 0.43).
***p-value
describes the comparison between the chosen primary diagnosis category and the combined group of all other primary diagnosis categories. SI conversion factor for 17-OH P4: nmol/l
= 3.03 * ng/ml.
between groups, albeit with no apparent clinically relevant
differences.
Cycle Characteristics
A total of 63% of patients were treated in a GnRH antagonist
protocol, whereas a long GnRH agonist protocol was used in
37% of patients. Final oocyte maturation was achieved using hCG
trigger in 58% of patients and using GnRH agonist trigger in 42%
of patients. In total, 64% of patients had a top-quality embryo for
transfer (Table 2).
The low 17-OH P4 group (<6 nmol/l) and the high 17-OH P4
group (>30 nmol/l) both had a significantly higher final follicle
count (p = 0.01) and a significantly higher number of oocytes
retrieved (p = 0.01) compared to the two remaining 17-OH P4
groups. Furthermore, total FSH dose, duration of stimulation
and the luteal phase support regime differed between groups
(Table 2).
Single embryo transfer was applied in 81% and double embryo
transfer in 19% of patients. There was no significant difference
between the number of embryos transferred across 17-OH
P4 groups (p = 0.66) A cleavage-stage embryo transfer was
performed on day 2 or 3 in 72% of patients, whereas 28% had
a blastocyst transfer on day 5. The study blastocyst transfer rate is
in line with the present blastocyst transfer rate for all public IVF
clinics in Denmark 2. The percentages of patients with blastocyst
transfer were comparable across the four 17-OH P4 groups (p =
0.42). Likewise, the mean embryo score was similar in different
17-OH P4 groups for both SET (p = 0.09) and DET transfers (p
= 0.92).
2Danish Fertility Society. Annual Report 2017.
Mid-Luteal 17-OH P4 Levels
The median 17-OH P4 concentration measured on OPU+7
was 13.2 nmol/l, range 0.5–129.0 nmol/l. The median P4
concentration was 113 nmol/l, range 16.3–1685.0 nmol/l. There
was a significant, positive association between P4 levels and 17-
OH P4 levels, p < 0.001 (Figure 2A). Thus, an increase of 100
nmol/l in serum P4 levels corresponded to an increase in serum
17-OHP4 levels of 9.5 nmol/l, 95%CI [9.0;9.9]. This ratio between
serum 17-OH P4 and serum P4 of ∼10% was constant with
increasing levels of P4, p = 0.67 (Figure 2B). However, a large
inter-individual difference in the secretion pattern of P4 and 17-
OHP4 was noticed. To illustrate this, the 19 patients in the cohort
with serum P4 values between 400–450 nmol/l are marked in red
in Figure 2A. Despite comparable levels of P4 in these patients,
the range of 17-OH P4 varied from levels as low as 4.4 nmol/l up
to 114 nmol/l.
Patients were equally distributed in the four chosen 17-
OH P4 groups. Out of the total cohort of 614 patients, 30%
(n = 183) had 17-OH P4 levels <6 nmol/l, 22% (n = 134)
had 17-OH P4 levels between 6 and 14 nmol/l, 21% (n =
132) had 17-OH P4 levels between 14.1 and 30 nmol/l and
finally, 27% (n = 165) had 17-OH P4 levels >30 nmol/l.
The 72 patients (12%) who were omitted from the final
regression analysis due to missing values of covariates, were
equally distributed across the four 17-OH P4 groups (p =
0.94).
Reproductive Outcomes
The overall rate for positive hCG per transfer was 47%
(291/614), the clinical pregnancy rate per transfer was 35%
(214/614) and the overall live birth rate per transfer was
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TABLE 2 | Descriptive data of controlled ovarian stimulation, oocytes, embryo transfer, and luteal phase support.
17-OH P4, nmol/l All <6 6-14 14.1-30 >30 p
Number of patients (n) 614 183 134 132 165
Protocol
Antagonist (%)
Long GnRH agonist (%)
63
37
51
49
58
42
61
39
81
19
<0.001
Total FSH dose (IU) 2,250
(500–7,350)
2,450
(900–6,750)
2,063
(788–7350)
2,475
(900–5025)
1,950
(500–7,350)
<0.001
Stim duration (days) 10.4 ± 2.0 10.4 ± 1.9 10.6 ± 2.1 10.6 ± 2.1 9.9 ± 1.9 0.006
Final follicle count >12mm on
trigger day
10
(1–29)
10
(1–29)
9
(1–22)
9
(3–20)
10
(1–26)
0.005
Mode of triggering for final oocyte
maturation
hCG (%) 58 67 72 61 35 <0.001
GnRH agonist (%) 42 33 28 39 65
Number of oocytes retrieved (n) 8
(1–28)
9
(1–23)
8
(1–26)
8
(1–24)
9
(2–28)
0.014
Number of fertilized oocytes (n) 8
(1–27)
8
(1–23)
8
(1–23)
7
(1–24)
8
(2–27)
0.033
Single embryo transfer (%)
Double embryo transfer (%)
81
19
79
21
79
21
83
17
83
17
0.661
At least one top quality embryo for
transfer (%) 64 66 59 70 64 0.160
Mean embryo score,
SET
DET
1.4 ± 0.6
1.7 ± 0.6
1.4 ± 0.6
1.7 ± 0.6
1.5 ± 0.7
1.7 ± 0.7
1.3 ± 0.5
1.6 ± 0.7
1.5 ± 0.7
1.6 ± 0.6
0.090
0.915
Day of transfer,
Cleavage-stage embryo transfer (%)
Blastocyst transfer (%)
72
28
72
28
72
28
77
23
68
32
0.418
Luteal phase support
Vaginal progesterone only (%)
+ 1 bolus of hCG (%)
+ 2 boluses of hCG (%)
Vaginal P + Gonapeptyl (%)
52
17
25
6
61
28
4
7
66
19
8
7
53
9
30
8
31
9
56
4
<0.001*
<0.001
<0.001
0.353
Descriptive data is presented as mean ± SD for continuous parametric data and as median (range) for continuous non-parametric data. Categorical data is presented as percentages
(%).*p-value describes the comparison between the chosen luteal phase support category and the combined group of all other luteal phase support categories. SI conversion factor
for 17-OH P4: nmol/l = 3.03
* ng/ml.
34% (207/614). The early pregnancy loss rate was 26%
(77/291), and the clinical pregnancy loss was 3% (7/214).
The minimum and maximum levels of 17-OH P4 in
patients with a live birth were 0.65 nmol/l and 114 nmol/l,
respectively.
When evaluating the association between mid-luteal 17-OH
P4 and reproductive outcomes, the optimal serum level of 17-
OH P4 was between 6 and 14 nmol/l. Below but also above
this level, the OR for positive hCG, clinical pregnancy and
live birth showed a non-linear pattern indicating a negative
impact on the reproductive outcomes (Figure 3). Thus, OR
for live birth in the low 17-OH P4 group was 0.61, 95% CI
[0.36;1.01], p = 0.06. Likewise, above the optimal 17-OH P4
range the OR for live birth was significantly decreased: OR
0.59, 95%CI [0.35;0.98], p = 0.04. As seen from Figure 3,
the association between 17-OH P4 and reproductive outcomes
displays a non-linear pattern and the negative impact of a
high mid-luteal 17-OH P4 level seems to be just as strong as
the negative impact of low 17-OH P4 in the peri-implantation
period.
In sensitivity analyses, adding trigger type, or protocol type
to the statistical model did not change estimates significantly.
Furthermore, when using 25/50/75 percentiles or 10/50/90
percentiles to define four 17-OH P4 groups, the same
non-linear pattern for reproductive outcomes was found as
seen with the a priori chosen 17-OH P4 groups presented
above, however, with smaller differences between groups
(Supplementary Figure 1).
For a reference person (30 years old, BMI 25 kg/m2, 8 follicles
on the day of trigger, late follicular phase P4 ≤4.77 nmol/l, non-
smoker) the chance of a live birth following blastocyst transfer
was 53%, 95% CI [42;64%] if mid-luteal 17-OH P4 was within the
optimal range (6–14 nmol/l). With mid-luteal 17-OH P4 levels
above the optimal range, the chance of a live birth decreased
significantly to 41%, 95% CI [31;52%], thus an absolute risk
difference of −12 percentage points, 95% CI [−22%;−0.01%],
p = 0.04. With mid-luteal 17-OH P4 levels below the optimal
level, the chance of a live birth was 43%, 95%CI [33;53%], thus
an absolute risk difference of −10 percentage points, 95% CI
[−21;0.1%], p= 0.07.
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FIGURE 2 | Correlation between mid-luteal serum 17-OH P4 and serum P4 in
614 women undergoing IVF treatment. (A) A significant positive correlation
was found between serum P4 and serum 17-OH P4, p < 0.001.Red dots
depict the 19 patients in the cohort with P4 400–450 nmol/l. (B) The ratio
between serum 17-OH P4 and serum P4 was constant at ∼10% throughout
the P4 range, p = 0.67. The linear regression line is marked in red.
No significant correlation betweenmid-luteal 17-OH P4 levels
and early pregnancy loss was found (Table 3).
Daytime Variations in Serum 17-OH P4
Levels
Figure 4 shows the individual daytime variations in mid-luteal
serum 17-OH P4 concentration in seven women undergoing IVF
treatment. Three of these women (#4, #5, and #6) had very low
endogenous 17-OH P4 production with median concentrations
during daytime between 1.9 and 3.8 nmol/l compared to 13.2
nmol/l for the total study cohort. It is seen from Figure 4 that in
patients with diminished luteal phase 17-OH P4 production (<6
nmol/l), serum concentrations of 17-OH P4 displayed a constant
pattern though out daytime without any significant fluctuations.
In contrast, in patients with 17-OH P4 levels above 6 nmol/l,
sudden fluctuations in 17-OH P4 occurred randomly in different
patients without any obvious common pattern. In patient #1, 17-
OH P4 increased 12.8 nmol/l in just 15min (12.45–13.00 p.m.).
This rise in concentration corresponds to an increase of 53%
compared to the median level for the day, and this rise occurred
even though LH levels were below the detection limit throughout
the study period (LH data not shown).
DISCUSSION
This prospective study, including 614 women undergoing IVF
and fresh embryo transfer, aimed at investigating whether the
mid-luteal serum 17-OH P4 concentration–used as an index of
corpus luteum (CL) function–affects the reproductive outcome.
The results suggest that positive hCG rates, clinical pregnancy
rates, and live birth rates are reduced outside the defined
optimal range for 17-OH P4 (6–14 nmol/l). Furthermore, for
the first time in IVF patients, we monitored the variation in
mid-luteal serum 17-OH P4 levels showing that patients with
diminished CL function displayed a constant hormone pattern
without any significant daytime fluctuations in serum 17-OH P4
concentrations.
FIGURE 3 | The association between mid-luteal serum 17-OH P4 levels and reproductive outcomes. OR for positive hCG, clinical pregnancy and live birth in different
17-OH P4 groups adjusted for maternal age, maternal BMI, day of embryo transfer, late follicular P4 levels, smoking and final number of follicles. P-values refer to the
pairwise comparison between each 17-OH P4 category and the reference group (6–14 nmol/l).
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FIGURE 4 | Individual daytime variation in mid-luteal serum 17-OH P4 levels in
women undergoing IVF treatment and fresh embryo transfer. (A) Daytime
variations in mid-luteal serum 17-OH P4 in four women treated in the long
GnRH agonist protocol and trigged for final oocyte maturation with hCG. All
patients received vaginal P4 for luteal phase support. Dotted lines depict 6,
14, and 30 nmol/l, respectively. (B) Daytime variations in mid-luteal serum
17-OH P4 in three women treated in the GnRH antagonist protocol and
trigged for final oocyte maturation with a bolus of GnRH agonist. All patents
received vaginal P4 for luteal phase support in combination with one
(patient#5 and #6) or two (patient #7) boluses of hCG on the day of oocyte
pick-up and 5 days later, respectively. Dotted lines depict 6 and 14 nmol/l.
The CL produces 17-OH P4, as well as, P4 during the luteal
phase (13). However, the secretion pattern of the two steroids
differs. Coinciding with the LH peak, an initial distinct 17-OH
P4 peak occurs reflecting the initial luteinisation and growth
of the theca lutein cells—the luteal cell-line capable of 17-
OH P4 synthesis (13). After 2–4 days of decline, the 17-OH
P4 levels increase again—now in parallel with P4 reaching a
second peak during the mid-luteal phase, followed by a decrease
toward the end of the luteal phase. In the natural cycle, the
mid-luteal ratio of 17-OH P4/P4 is reported to be 10–20%
(13, 23–26). We found a similar ratio of ∼10% in our cohort
and this ratio did not change significantly with increasing
levels of P4. The large inter-individual differences seen in the
secretion pattern of P4 and 17-OH P4 underline that the CL
function is highly individual, and that comparable values of P4
in individual patients may correspond to very diverse levels of
17-OH P4. Furthermore, three out of seven randomly chosen
patients who participated in the daytime monitoring displayed
severely reduced endogenous 17-OH P4 levels throughout the
day (median levels 1.9–3.8 nmol/l). These concentrations are
even lower than seen during the mid-luteal phase of the natural
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cycle (∼6 nmol/l) (18). Additionally, the very low serum 17-
OH P4 levels were accompanied by low serum P4 levels (36–
55 nmol/l). The exogenous vaginal P4 supplementation induces
a serum P4 level of ∼30–40 nmol/l, thus underlining that
the abovementioned three patients had a severely diminished
endogenous P4 secretion. This occurred although two of the
patients had 17 and 19 follicles, respectively, on the day of trigger.
Thus, the CL function is individual, and a large number of CLs
do not necessarily warrant a high steroid output in the mid-luteal
phase. Furthermore, it seems that a severely decreased mid-luteal
CL function is not a rare finding following IVF treatment despite
a sufficient trigger regimen and luteal phase support.
The biological effect of 17-OH P4 is not well-described.
Whereas, P4 has a fundamental impact on the decidualization
process (27), the maternal immunological adaption in early
pregnancy (28) and the dampening of uterine contractions at
the time of implantation (29), the endogenous 17-OH P4 has
only very weak progestogen effects (30). The binding affinity
of 17-OH P4 to both P4 receptors (PR-A and PR-B) is only
1% of that of P4. Furthermore, upon binding, the capacity of
17-OH P4 to activate subsequent gene expression is very low
and only ∼0.12% of that of P4 (30). Thus, even though P4 and
17-OH P4 are structurally similar and are secreted in parallel
from the CL, they seem to work in different ways. In serum, P4
is tightly bound to cortisol-binding protein (18%) and loosely
bound to albumin (80%) whereas only 2% of P4 is unbound
(free) (24, 31). The free form of P4 is available for diffusion
out of capillaries, into cells where it exerts its function (32).
A fraction of the secreted P4 and 17-OH P4 from the CL is
transported directly to the uterus through a counter-current
exchange mechanism from the utero-ovarian veins into the
utero-ovarian arteries driven by a large concentration gradient
(33, 34). Thismechanismmay function to secure a high biological
steroid concentration from the site of production (the ovaries)
directly to the target organ (the endometrium) (34, 35). Another
fraction of secreted P4 and 17-OH P4 from the CL enters
circulation directly via the ovarian veins, which terminate in the
inferior vena cava (right) and the renal vein on the left (36). The
binding affinity of 17-OH P4 to cortisol-binding protein (CBP)
is much greater than that of P4 and close to that of cortisol
(24). It can be speculated that 17-OH P4 acts by displacing
P4 and cortisol from CBP, thereby increasing the free active
hormone concentration locally in the ovarian veins. Thus, this
mechanism will ensure a high, free P4 concentration facilitating
the counter-current transport from the venous to the arterial
vascular bed and hence, an increased direct transport of P4 to the
endometrium.
It should be emphasized that natural, endogenous 17-OH P4
differs chemically and biologically from the synthetic progestin
17-OH P4 caproate (17-OHPC). The latter is a synthetic
progestogen (compound with progesterone-like action) and is
not produced endogenously (37). The 17-OHPC binds more
avidly to the P4 receptor than natural 17-OH P4, eliciting a
sustained and robust progestogen effect on the endometrium
(30). Thus, 17-OHPC can be used as luteal phase support (IM
administration) whereas monotherapy with natural 17-OH P4–
with a very weak direct progestogen effect—probably would be
inefficient in terms of rescuing the luteal phase following IVF
treatment.
From a clinical viewpoint, 17-OH P4 may be used as a
direct biomarker for luteal phase function, as 17-OH P4 is not
supplied as part of the luteal P4 supplementation regimen. Thus,
the measured 17-OH P4 reflects the endogenous production
predominantly from the CL, as only a minor fraction (∼0.5
nmol/l) of circulating mid-luteal 17-OH P4 originates from the
adrenal glands (23, 26).
Our findings of a non-linear association between 17-OH
P4 levels and the reproductive outcomes is in line with other
studies examining luteal phase steroid profiles. Following frozen-
thawed embryo transfer, work by Yovich et al. (8) and Alsbjerg
et al. (10) both showed a diminished chance of ongoing
pregnancy if serum P4 was above or below a defined optimal P4
range. Similarly, in a previous paper using the present patient
cohort, we found a consistently non-linear pattern describing
the association between early and mid-luteal P4 levels and
reproductive outcomes. Thus, suggesting that both low, as well
as, high luteal P4 levels reduce the chance of a positive pregnancy
outcome following fresh embryo transfer (9). In that study, P4
monitoring was performed during the early luteal phase (2–3
days following OPU) or in the mid-luteal phase (OPU+5). The
same pattern emerged in this study, measuring serum 17-OH P4
on OPU+7.
Taken together, the non-linear pattern between luteal steroid
levels and reproductive outcomes seems to apply both to P4 and
17-OH P4, to different days in the luteal phase (2, 3, 5, or 7 days
after OPU) and to both the fresh and frozen embryo transfer cycle
(8–11). Furthermore, the above-mentioned studies all found a
consistency in the absolute risk reduction (14–20 percentage
points) below or above the defined P4 which is in line with our
present results.
In this study, daytime monitoring of 17-OH P4 showed that
patients with a diminished luteal phase function (17-OH P4
<6 nmol/l) displayed a constant 17-OH P4 pattern throughout
daytime without any significant fluctuations in serum levels.
Thus, measurement of luteal 17-OH P4 concentrations will
accurately detect patients with low endogenous 17-OH P4 levels
and, thus, a decreased corpus luteum function. In patients with
higher 17-OHP4 concentrations, fluctuations in serum 17-OHP4
concentrations occur in a random fashion without any obvious
common pattern between patients.
The possible clinical effect of serum fluctuations is
demonstrated in patient #7 (Figure 4). When measuring
17-OH P4 levels at 8.00 a.m., the patient would be classified
in the optimal 17-OH P4 range between 6 and 14 nmol/l.
However, if measurements were performed at 12.00 p.m., she
would be categorized in the 14.1–30 nmol/l group. Similarly,
patient #2 shift between 17-OH P4 group 14.1–30 and >30
nmol/l depending on the time of measurements. Thus, the figure
demonstrates that when 17-OH P4 monitoring is done 7 days
after OPU, there is a risk of misclassification of patients if serum
17-OH P4 >6 nmol/l. The finding, that the magnitude of the
17-OH P4 fluctuations depends on the 17-OH P4 concentration,
is in total agreement with the P4 daytime variation on OPU+7
previously shown by our group (14).
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We monitored 17-OH P4 on OPU+7 to explore whether
the non-linear association between progestogen levels and
reproductive outcome was still present at the time of
implantation compared to earlier luteal measurements (2,
3, or 5 days following OPU) (9). Based on the present results,
this seems to be the case. Performing the luteal monitoring
early in the luteal phase, allows for an intervention based on the
results. Thus, better reproductive outcomes may be obtained by
additional exogenous luteal P4 support to the low P4 or 17-OH
P4 group and by segmentation followed by subsequent embryo
transfer in a frozen/thawed cycle in case of a high P4 or 17-OH
P4 level. In a clinical setting monitoring of P4 or 17-OH P4 on
OPU+7 is disadvantageous as the clinical consequence of a “too
low” or “too high” progestogen level is limited. Thus, at this
time of cycle, the embryo is already transferred and the effect of
administering additional exogenous P4 during peri-implantation
may be reduced compared to administration earlier in the luteal
phase (38). Furthermore, in some IVF patients, peak levels of P4
and 17-OH P4 are seen already on day 5–6 and following this P4
and 17-OH P4 start to decrease. It could be hypothesized that
some of the patients with low 17-OH P4 measured on day 7,
had sufficient levels of 17-OH P4 earlier in the luteal phase and
therefore are classified as “false low” on day 7. These patients
could theoretically belong to a group with better pregnancy
chance compared to patients with consistently low 17-OH P4
levels throughout the luteal phase. This misclassification of some
of the patients could potentially affect the OR in the low 17-OH
P4 group and underestimate the effect of low 17-OH P4 on the
chance of pregnancy.
Whether the 17-OH P4 monitoring offers a clinical advantage
compared to the more traditional P4 monitoring may be
questioned. The 17-OH P4 does not seem to display a more
stable luteal daytime pattern in patients with sufficient CL
function compared to P4 (14). Furthermore, whereas the
analytical performance of P4 immunoassays is generally high, the
immunoassays available for the quantification of 17-OH P4 suffer
from important analytical limitations (39, 40). The specificity of
17-OH P4 measured by immunoassays is critically limited due
to reduced reproducibility and cross reactivity with particularly
P4 (40). To account for this, 17-OH P4 quantification must be
performed using LC-MS/MS to obtain sufficient accuracy. This
requires moremanual work for themedical laboratory technician
compared to a P4 quantification using standard immunoassays
and this more than triples the expense per sample. Finally, as
demonstrated by Figure 2A, some patients display a low mid-
luteal 17-OH P4 level even though the concomitant measured P4
level seems sufficient. This phenomenon may reflect an isolated
defect in the function of the luteinized theca cells but a sufficient
P4 output from the luteinized granulosa cells (13) and may lead
to a misclassification of the patient.
The key strengths of the present study include its prospective
design, the large cohort of patients and the systematic approach
to the handling of confounding factors by use of Directed
Acyclic graphs minimizing the risk of collider stratification
(41). Furthermore, all patients received the same type and dose
of vaginal P4 supplementation in the luteal phase ensuring
a basis for comparison between patients. Furthermore, the
participants included in the study were unselected broadening
the generalizability of the findings.
In conclusion, this study shows for the first time that the
chance of a live birth is reduced by ∼10 percentage points
below, but also above the defined optimal range for 17-OH
P4 measured on OPU+7. This finding supports the emerging
evidence that the absolute concentrations of luteal P4 seem to
affect the reproductive outcomes following IVF treatment. Based
on the present study, luteal monitoring of 17-OH P4 levels alone
does not seem to offer a better insight into the CL function
compared to the monitoring of total P4 levels.
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